Shen Zhen-zhou, Liu Guang-yu, Su Feng-xi, He Ping-qing, Yang Ming-tian, Shi Jun-yi, Sheng Yuan, Zou Qiang, Li Ya-fen
Department of Breast, Cancet Hospital, Fudan University, Shanghai 200032, China.
Zhonghua Zhong Liu Za Zhi. 2005 Feb;27(2):126-8.
To investigate the clinical response, pathological complete response (pCR), tumor resection rate and safety of neoadjuvant chemotherapy with docetaxel and epirubicin (ET) for locally advanced breast cancer (LABC).
From March to December 2001, 40 women with LABC, aged from 28-67 (medium 48) years were alloted. Twenty patients had clinical stage IIIa disease, 15 had stage IIIb disease and 5 stage IV patients who had ipsilateral sura-clavicular metastasis. The dose was: epirubicin (E) 60 mg/m2, docetaxel (T) 75 mg/m2 every 3 weeks, with G-CSF given preventively. After 2 cycles of ET, a pilot clinical response evaluation was performed by investigators for each patient to decide if she should receive another 1-2 cycles of ET before surgery or radiation therapy.
Thirty-eight patients received 2-3 cycles of ET regimen. The pCR, clinical complete response (cCR) and clinical partial response (cPR) rates were 15.0%, 20.0% and 52.5%, respectively. Tumor resection rate in this group was 92.5%. Incidence of III/IV Grade neutropenia was 8.4%/14.0% of cycles, and 3 patients suffered from neutropenia with fever. Non-hematological adverse events were alopecia, nausea, vomiting, fluid retention, myalgia, arthralgia and nail disorders, which were mild to moderate.
Neo-adjuvant chemotherapy with a combination of docetaxel and epirubicin is effective and well tolerated by women with locally advanced breast cancer.
探讨多西他赛联合表柔比星（ET）新辅助化疗治疗局部晚期乳腺癌（LABC）的临床疗效、病理完全缓解（pCR）、肿瘤切除率及安全性。
2001年3月至12月，分配40例LABC女性患者，年龄28 - 67岁（中位年龄48岁）。20例患者为临床Ⅲa期疾病，15例为Ⅲb期疾病，5例为伴有同侧锁骨上转移的Ⅳ期患者。剂量为：表柔比星（E）60 mg/m²，多西他赛（T）75 mg/m²，每3周一次，并预防性给予粒细胞集落刺激因子（G-CSF）。ET方案化疗2周期后，研究者对每位患者进行初步临床疗效评估，以决定患者在手术或放疗前是否应再接受1 - 2周期的ET方案化疗。
38例患者接受了2 - 3周期的ET方案化疗。pCR、临床完全缓解（cCR）和临床部分缓解（cPR）率分别为15.0%、20.0%和52.5%。该组肿瘤切除率为92.5%。Ⅲ/Ⅳ级中性粒细胞减少症的发生率为每周期的8.4%/14.0%，3例患者发生中性粒细胞减少伴发热。非血液学不良事件包括脱发、恶心、呕吐、液体潴留、肌痛、关节痛和指甲病变，程度为轻至中度。
多西他赛联合表柔比星新辅助化疗对局部晚期乳腺癌女性患者有效且耐受性良好。
